Gila Therapeutics

Name

Gila Therapeutics

Legal name

Gila Therapeutics, Inc.

Website

https://gilatherapeutics.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Biopharmaceutical Therapeutics

NAICS

Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

Keywords

• Obesity therapeutics
• Topical lingual delivery
• Peptide hormone therapy
• Cardiometabolic treatments
• Clinical-stage biotech

Headquarters

HQ city

Minneapolis

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Fundraising via Securities Offering: Clinical-stage biotech company raising capital through SEC Rule 506(b) private placement to fund ongoing research and development of topical lingual therapeutics.
2. Future Pharmaceutical Product Sales: As a clinical-stage biotech, Gila has no current revenue. Future revenue is expected to come from commercializing topical lingual therapeutics for obesity and metabolic disorders, potentially through licensing deals with pharmaceutical partners or direct product sales.

Go-to-market motion1 record

Core offering

Gila Therapeutics is a clinical-stage biotech company developing a proprietary Topical Lingual Signaling Platform that delivers peptide hormones (PYY, GLP-1, amylin, leptin) via oral dissolving tablets to activate brain satiety centers through the tongue-brain neural pathway without systemic exposure. Its lead candidate, Topical Lingual PYY, has completed Phase I trials with zero treatment-related adverse events, targeting obesity, type 2 diabetes, and associated metabolic disorders.

Product overview

Gila Therapeutics is developing a portfolio of peptide hormone therapies delivered via its proprietary Topical Lingual Neural Signaling Platform. The core product, Topical Lingual PYY, has completed Phase I trials, while Topical Lingual GLP-1 and additional hormone targets (amylin, leptin) are under development. All products leverage the novel tongue-brain pathway to activate satiety centers without systemic exposure, using Catalent Zydis ODT fast-dissolve technology.

Differentiator

Problem solved

Functional benefit

Products and services

• Topical Lingual PYY A first-in-class peptide hormone therapy delivered via a melt-on-tongue tablet that activates satiety centers in the brain through the tongue-brain neural pathway without systemic exposure. Completed Phase I clinical trial with zero treatment-related adverse events. Intended for treatment of obesity and cardiometabolic disorders.
• Topical Lingual GLP-1 A topical lingual formulation of GLP-1 hormone targeting the same tongue-brain neural signaling pathway for treatment of obesity and type 2 diabetes. Currently under development.
• Topical Lingual Hormone Platform A proprietary technology platform leveraging the tongue-brain neural connection to deliver peptide hormones (PYY, GLP-1, amylin, leptin, and others) noninvasively, activating brain satiety centers without systemic exposure or side effects. Uses Catalent Zydis ODT delivery technology.

Quantifiable outcome

• Phase I clinical trial: strong efficacy with zero treatment-related adverse events (AEs) or serious adverse events (SAEs)
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• University of FloridacoreStrategic or Co-development PartnerUniversity of Florida is one of Gila Therapeutics' key academic research partners, collaborating on advancing the topical lingual signaling platform technology for obesity and metabolic disorder treatments. The partnership leverages the university's research capabilities in endocrinology and metabolic research.
• University of PennsylvaniacoreStrategic or Co-development PartnerUniversity of Pennsylvania is a strategic research partner, contributing expertise in neuroscience and behavior research through advisors like Harvey Grill, PhD (Professor of Behavior Neuroscience and former President of The Obesity Society) and Mathew Hayes, PhD (Albert J. Stunkard Professor in Psychiatry). The partnership advances understanding of neural signaling pathways controlling food intake and body weight regulation.
• Eli Lilly and CompanycoreStrategic or Co-development PartnerEli Lilly is shown as a pharmaceutical partnership in Gila's logo section. The company is collaborating with Gila to advance the world's inaugural Topical Lingual PYY and GLP1 to market. This partnership combines pharmaceutical development expertise with Gila's novel neural signaling platform technology.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Emerging players

• BioAge Labs: Clinical-stage biotech using AI-driven discovery for metabolic disease targets including obesity; analogous clinical-stage metabolic platform chasing the same underserved patient population.
• Lexicon Pharmaceuticals: Small-molecule metabolic disease developer (with Gila director Praveen Tyle's prior involvement) advancing type 2 diabetes therapies; comparable metabolic R&D stage and indication focus.
• Carmot Therapeutics: Clinical-stage metabolic disease biotech acquired by Roche, developing peptide incretins for obesity/diabetes; comparable disease focus and modality for the same competitive category.
• NodThera: Clinical-stage neuroscience company where Gila's CMO previously worked; targets inflammatory mechanisms relevant to metabolic dysfunction and overlapping scientific leadership profiles.
• Metsera: Recently launched obesity-focused biotech with significant institutional backing; pursues novel mechanisms in obesity and cardiometabolic disease, directly relevant benchmark for early-stage obesity therapeutics.

Others

• Orexigen Therapeutics: Founded by Gila scientific advisor Michael Cowley and developer of Contrave; relevant historical precedent for obesity-focused peptide/small-molecule platforms and Cowley's institutional track record.

Broad incumbents

• Eli Lilly and Company: Major pharmaceutical incumbent and Gila's disclosed strategic partner for PYY and GLP-1; dominant obesity player with Mounjaro/Zepbound and the most direct comparison for any non-systemic obesity entrant.
• Novo Nordisk: Global GLP-1 leader with Wegovy/Ozempic; defines efficacy and safety benchmarks and competitive intensity in obesity and type 2 diabetes therapeutics that Gila's platform is targeting.

Direct peers

• Zealand Pharma: Clinical-stage peptide therapeutics company developing glepaglutide and dasiglucagon for metabolic and obesity indications; directly comparable peptide platform addressing the same metabolic disorder space.
• Structure Therapeutics: Clinical-stage company developing oral small-molecule GLP-1 receptor agonists (e.g., GSBR-1290) for obesity and diabetes; comparable pursuit of needle-free, oral peptide-like therapies in obesity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/gila-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gila Therapeutics